{"id":156,"date":"2025-07-11T01:35:58","date_gmt":"2025-07-11T01:35:58","guid":{"rendered":"https:\/\/www.newsbeep.com\/us\/156\/"},"modified":"2025-07-11T01:35:58","modified_gmt":"2025-07-11T01:35:58","slug":"fulgent-to-announce-second-quarter-2025-financial-results-on-friday-august-1-2025","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us\/156\/","title":{"rendered":"Fulgent to Announce Second Quarter 2025 Financial Results on Friday, August 1, 2025"},"content":{"rendered":"

EL MONTE, Calif.–(BUSINESS WIRE)–Fulgent Genetics, Inc. (NASDAQ: FLGT) (\u201cFulgent\u201d or the \u201cCompany\u201d), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2025 financial results before the market opens on Friday, August 1, 2025. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions.<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe call may be accessed through a live audio webcast on the Investor Relations section of the Company\u2019s website, http:\/\/ir.fulgentgenetics.com<\/a>. An audio replay will be available at the same location.<\/p>\n

\nAbout Fulgent<\/p>\n

\nFulgent is a technology-based company with a well-established laboratory services business and a therapeutic development business. Fulgent\u2019s laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Fulgent\u2019s therapeutic development business is focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The Company aims to transform from a diagnostic business into a fully integrated precision medicine company.<\/p>\n

Contacts <\/p>\n

\nInvestor Relations Contact:
The Blueshirt Group
\n
Lauren Sloane, Lauren@blueshirtgroup.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"EL MONTE, Calif.–(BUSINESS WIRE)–Fulgent Genetics, Inc. (NASDAQ: FLGT) (\u201cFulgent\u201d or the \u201cCompany\u201d), a technology-based company with a well-established…\n","protected":false},"author":2,"featured_media":157,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[50],"tags":[200,79],"class_list":["post-156","post","type-post","status-publish","format-standard","has-post-thumbnail","category-genetics","tag-genetics","tag-science"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/156","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=156"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/156\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/157"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=156"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=156"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=156"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}